Work

A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial)

Year: 2025

Type: article

Study design: Clinical Trial

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2025.08.028

Authors: D.E. Spratt, T.G. Karrison, H.M. Sandler, E. Posadas, R.C. Chen, R.E. Wallace, J.I. Monroe, L.G. Gomella, R.T. Dess, A.D. Vassil, A. Ebacher, T. Gunter, R.J. Lee, J.W. DiNome, S.E. Delacroix, J.M. Michalski, X. Shen, T. Johnson, P.L. Nguyen, F.Y. Feng

Institutions: University Hospitals Seidman Cancer Center, Case Western Reserve University, NRG Oncology, Cedars-Sinai Medical Center, University of Kansas Medical Center, Mays Cancer Center at UT Health San Antonio, Thomas Jefferson University, Sidney Kimmel Cancer Center, University of Michigan, Cleveland Clinic, University of Oklahoma Health Sciences Center, Intermountain Medical Center, Mary Bird Perkins Cancer Center, Washington University in St. Louis, American College of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of California, San Francisco

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415170050

FWCI: 4.559

Cites:

Cited by: 7

Related to: 10